Aptus Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Aptus Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36M	Buy	24,206 +2,871	+13%	+$149K	0.01%	570
2026 Q1	$1.02M	Buy	21,335 +4,502	+27%	+$197K	0.01%	580
2025 Q4	$650K	Buy	16,833 +2,750	+20%	+$105K	﹤0.01%	674
2025 Q3	$497K	Buy	14,083 +3,369	+31%	+$122K	﹤0.01%	700
2025 Q2	$386K	Buy	+10,714	New	+$355K	﹤0.01%	745

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aptus Capital Advisors's RPRX Position: Q2 2026 in Review

Aptus Capital Advisors increased its Royalty Pharma (RPRX) stake by 13% in Q2 2026, buying an estimated $149K and bringing the position to 24,206 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #570.

Aptus Capital Advisors first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Aptus Capital Advisors held 24,206 shares of Royalty Pharma worth $1.36M as of Q2 2026.
Aptus Capital Advisors bought 2,871 Royalty Pharma shares in Q2 2026, an estimated $149K.
Royalty Pharma made up 0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #570 holding.
Aptus Capital Advisors first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.